| Semaglutide GLP-1 receptor agonist | FDA-approved | FDA-approved products exist. Broad copy compounding is not a Category 1 peptide-bulk pathway, and FDA flags unapproved GLP-1 products and salt forms as safety risks. FDA's May 1, 2026 proposal to exclude semaglutide from the 503B outsourcing-facility bulks list on a 'no clinical need' finding closed for comment on or about July 30, 2026. As of August 22, 2026 FDA had issued no final determination and no follow-on Federal Register document, and no court challenge to the proposal had been filed. Separately, on July 28, 2026 FDA published revised draft product-specific guidances for generic semaglutide — a bioequivalence-recommendation update, not an approval, and not a change to compounding law. Comment period on the proposed 503B bulks-list exclusion closed July 30, 2026 (docket FDA-2018-N-3240). Watching for a final FDA determination; none had issued as of August 22, 2026. | FDA-approved products, FDA GLP-1 compounding safety communications, the May 2026 proposed 503B bulks-list exclusion with a Federal Register check through August 22, 2026, and FDA's July 2026 revised draft generic-peptide guidances. |
| Tirzepatide Dual GIP/GLP-1 receptor agonist | FDA-approved | FDA-approved products exist. Copy compounding is constrained by approved-drug and shortage rules, not Category 1 peptide-bulk status. FDA's May 1, 2026 proposal to exclude tirzepatide from the 503B outsourcing-facility bulks list on a 'no clinical need' finding closed for comment on or about July 30, 2026. As of August 22, 2026 FDA had issued no final determination and no follow-on Federal Register document. Separately, on July 28, 2026 FDA published revised draft product-specific guidances for generic tirzepatide — a bioequivalence-recommendation update, not an approval, and not a change to compounding law. Comment period on the proposed 503B bulks-list exclusion closed July 30, 2026 (docket FDA-2018-N-3240). Watching for a final FDA determination; none had issued as of August 22, 2026. | FDA-approved products, FDA GLP-1 compounding safety communications, the May 2026 proposed 503B bulks-list exclusion with a Federal Register check through August 22, 2026, and FDA's July 2026 revised draft generic-peptide guidances. |
| Liraglutide GLP-1 receptor agonist | FDA-approved | FDA-approved products exist. This is an approved-drug pathway, not a Category 1 peptide-bulk listing. FDA's May 1, 2026 proposal to exclude liraglutide from the 503B outsourcing-facility bulks list on a 'no clinical need' finding closed for comment on or about July 30, 2026, and FDA had issued no final determination as of August 22, 2026. Liraglutide is also covered by FDA's July 28, 2026 revised draft product-specific guidances for generic peptide products. Comment period on the proposed 503B bulks-list exclusion closed July 30, 2026 (docket FDA-2018-N-3240). Watching for a final FDA determination; none had issued as of August 22, 2026. | FDA-approved product records, the May 2026 proposed 503B bulks-list exclusion with a Federal Register check through August 22, 2026, and FDA's July 2026 revised draft generic-peptide guidances. |
| Tesamorelin GHRH analog | FDA-approved | FDA-approved product exists. Any compounding analysis starts from approved-drug rules rather than Category 1 bulk status. | FDA-approved product records. |
| PT-141 / Bremelanotide Melanocortin receptor agonist | FDA-approved | FDA-approved product exists for a specific indication. That approval does not validate non-approved indications. | FDA-approved product records. |
| Oxytocin Neuropeptide hormone | FDA-approved | FDA-approved drug products exist. This is not a consumer peptide-bulk compounding status. | FDA-approved product records. |
| Elamipretide Mitochondria-targeted peptide | FDA-approved | FDA-approved product exists under an approved-drug pathway. It is not a Category 1 compounded bulk peptide. | FDA-approved product records. |
| GHK-Cu Glycyl-L-histidyl-L-lysine copper | Category 1PCAC review | Category 1 in FDA's 503A materials for non-injectable routes. Injectable GHK-Cu is not on that footing and is not authorized for compounding. Its position moved in April 2026: injectable GHK-Cu was one of the twelve peptides shifted off FDA's active category 2 table into the new 'nominated but withdrawn' table. FDA still publishes its safety-risk finding, and the substance is no closer to being compoundable — a withdrawn nomination is a nomination that will not be decided, not a clearance. Law-firm reporting from the July 2026 PCAC meeting says FDA signalled a further PCAC consultation on GHK-Cu and four other peptides; FDA has published no meeting notice, docket, or date for it, so we treat the timing as unconfirmed. A second peptide PCAC meeting including GHK-Cu is reported but unscheduled. Watching the FDA advisory committee calendar and the Federal Register. | FDA 503A bulk-substance pages and safety-risk page, checked August 22, 2026. The follow-on PCAC consultation is secondary reporting only — no FDA primary source exists yet. |
| NAD+ Nicotinamide adenine dinucleotide | Category 1Not a peptide | Category 1 in the current FDA 503A list. It is a coenzyme, not a peptide, and Category 1 is not FDA drug approval. | Current FDA 503A category PDF. |
| Vasoactive intestinal peptide VIP | Category 1 | Category 1 in the current FDA 503A list if all compounding conditions are met. | Current FDA 503A category PDF. |
| Sermorelin GHRH (1-29) | Other compoundable path | Not shown as a May 2026 Category 1 peptide-bulk entry. Peptide Garden tracks it separately because its profile cites a prior FDA approval, withdrawal not for safety or effectiveness, and an established compounding pathway. | Secondary Peptide Garden profile context; not counted as a Category 1 tracker entry. |
| Kisspeptin-10 Kisspeptin fragment | Category 2InvestigationalNot compoundable | Category 2 under 503A, added September 29, 2023, and still there. After FDA's April 2026 restructure, kisspeptin-10, ipamorelin acetate, GHRP-2 (injectable/nasal routes), and GHRP-6 are the four peptides left in the active category 2 table — everything else moved to the 'nominated but withdrawn' table. Treat as not currently compoundable. | FDA's category 2 table, re-read line by line on August 22, 2026, plus profile clinical-trial context. |
| Ipamorelin acetate Growth hormone secretagogue | Category 2PCAC reviewNot compoundable | Category 2 for 503B outsourcing facilities, added September 29, 2023, and still there — one of four peptides remaining in FDA's active category 2 table. Its separate 503A nomination was withdrawn, so ipamorelin acetate is the one substance that appears in both of FDA's tables at once. Not a Category 1 503A bulk substance. | FDA safety-risk page, re-read line by line on August 22, 2026, and prior PCAC review context; no current Category 1 listing identified. |
| GHRP-2 Growth hormone releasing peptide-2 | Category 2Not compoundable | Category 2 for injectable and nasal routes in FDA's safety-risk materials. Treat as not currently compoundable. | FDA safety-risk page. |
| GHRP-6 Growth hormone releasing peptide-6 | Category 2Not compoundable | Category 2 in FDA's safety-risk materials. Treat as not currently compoundable. | FDA safety-risk page. |
| Ibutamoren MK-677 | Category 2Not compoundableNon-peptide secretagogue | Category 2 in the current FDA 503A list. Included because it is frequently grouped with growth hormone peptides in consumer searches. | Current FDA 503A category PDF. |
| BPC-157 BPC-157 free base and acetate salt PCAC hub | PCAC recommendedPCAC reviewNot compoundable | Not on the 503A Bulks List and not Category 1. On July 23, 2026 the FDA advisory committee voted to recommend BPC-157, free base and acetate salt, for the list — 8 yes, 6 no, 1 abstain as reported. FDA's own review team had recommended against all seven substances on the agenda, and its slides state that BPC-157 acetate 'is not well-characterized.' A recommendation is advisory. FDA has taken no action, so BPC-157 is not legal to compound today. FDA must publish a proposed rule and run notice-and-comment before anything changes. None had issued as of August 22, 2026. | FDA's July 2026 PCAC meeting page, voting questions, and presentation slides, plus a Federal Register check on August 22, 2026 showing no proposed rule or list change. Tallies are as reported by legal and trade press; FDA published no official tallies, minutes, or transcript. |
| KPV KPV free base and acetate salt PCAC hub | PCAC recommendedPCAC reviewNot compoundable | Not on the 503A Bulks List and not Category 1. On July 23, 2026 the FDA advisory committee voted to recommend KPV, free base and acetate salt, for the list — 8 yes, 6 no, 1 abstain as reported, against FDA's own review team's recommendation to exclude it. FDA's evaluated use was wound healing and inflammatory conditions. A recommendation is advisory. FDA has taken no action, so KPV is not legal to compound today. FDA must publish a proposed rule and run notice-and-comment before anything changes. None had issued as of August 22, 2026. | FDA's July 2026 PCAC meeting page, voting questions, and presentation slides, plus a Federal Register check on August 22, 2026 showing no proposed rule or list change. Tallies are as reported; FDA published no official tallies, minutes, or transcript. |
| TB-500 TB-500 free base and acetate salt PCAC hub | PCAC recommendedPCAC reviewNot compoundable | Not on the 503A Bulks List and not Category 1. On July 23, 2026 the FDA advisory committee voted to recommend TB-500, free base and acetate salt, for the list — 8 yes, 6 no, 1 abstain as reported, against FDA's own review team's recommendation to exclude it. FDA's evaluated use was wound healing. FDA opened the meeting with a talk on 'conflated bulks': one trade name can map to different sequences from different suppliers, which is exactly the TB-500 problem — the name is used for both full-length thymosin beta-4 and a short fragment. A recommendation is advisory. FDA has taken no action, so TB-500 is not legal to compound today. FDA must publish a proposed rule and run notice-and-comment before anything changes. None had issued as of August 22, 2026. | FDA's July 2026 PCAC meeting page, voting questions, and presentation slides, plus a Federal Register check on August 22, 2026 showing no proposed rule or list change. FDA's agenda names the substance simply as 'TB-500 (free base) / TB-500 acetate.' Tallies are as reported; FDA published no official tallies, minutes, or transcript. |
| MOTS-c MOTS-c free base and acetate salt PCAC hub | PCAC recommendedPCAC reviewNot compoundable | Not on the 503A Bulks List and not Category 1. On July 23, 2026 the FDA advisory committee voted to recommend MOTS-c, free base and acetate salt, for the list — 7 yes, 5 no, 2 abstain as reported, against FDA's own review team's recommendation to exclude it. FDA's evaluated uses were obesity and osteoporosis. A recommendation is advisory. FDA has taken no action, so MOTS-c is not legal to compound today. FDA must publish a proposed rule and run notice-and-comment before anything changes. None had issued as of August 22, 2026. | FDA's July 2026 PCAC meeting page, voting questions, and presentation slides, plus a Federal Register check on August 22, 2026 showing no proposed rule or list change. Tallies are as reported; FDA published no official tallies, minutes, or transcript. |
| Semax Semax free base and acetate salt PCAC hub | PCAC recommendedPCAC reviewNot compoundable | Not on the 503A Bulks List and not Category 1. On July 24, 2026 the FDA advisory committee voted to recommend Semax, free base and acetate salt, for the list — 8 yes, 5 no, 1 abstain as reported, against FDA's own review team's recommendation to exclude it. FDA's evaluated uses were cerebral ischemia, migraine, and trigeminal neuralgia. A recommendation is advisory. FDA has taken no action, so Semax is not legal to compound today. FDA must publish a proposed rule and run notice-and-comment before anything changes. None had issued as of August 22, 2026. | FDA's July 2026 PCAC meeting page, voting questions, and presentation slides, plus a Federal Register check on August 22, 2026 showing no proposed rule or list change. Tallies are as reported; FDA published no official tallies, minutes, or transcript. |
| Emideltide / DSIP Delta sleep-inducing peptide PCAC hub | PCAC reviewNot compoundable | Not on the 503A Bulks List and not Category 1. Emideltide was the only one of the seven substances the advisory committee voted against on July 24, 2026 — 6 yes, 7 no, 1 abstain as reported. FDA's evaluated uses were opioid withdrawal, chronic insomnia, and narcolepsy. Both the FDA review team and the committee landed against inclusion, so there is no pathway in progress. No FDA action expected from this vote. Treat as not compoundable. | FDA's July 2026 PCAC meeting page, voting questions, and presentation slides, plus a Federal Register check on August 22, 2026. Tallies are as reported; FDA published no official tallies, minutes, or transcript. |
| Epitalon Epitalon free base and acetate salt PCAC hub | PCAC recommendedPCAC reviewNot compoundable | Not on the 503A Bulks List and not Category 1. On July 24, 2026 the FDA advisory committee voted to recommend Epitalon, free base and acetate salt, for the list — 7 yes, 4 no, 1 abstain as reported (some outlets reported 7-5-1; only 12 members were eligible to vote on this substance). FDA's evaluated use was insomnia. A recommendation is advisory. FDA has taken no action, so Epitalon is not legal to compound today. FDA must publish a proposed rule and run notice-and-comment before anything changes. None had issued as of August 22, 2026. | FDA's July 2026 PCAC meeting page, voting questions, final meeting roster, and presentation slides, plus a Federal Register check on August 22, 2026 showing no proposed rule or list change. Tallies are as reported; FDA published no official tallies, minutes, or transcript. |
| AOD-9604 hGH fragment 176-191 | PCAC reviewNot compoundable | Not currently Category 1. FDA PCAC reviewed AOD-9604-related bulk substances in December 2024; no current Category 1 listing identified. The substance sits in FDA's 'nominated but withdrawn' table, where FDA continues to publish its safety-risk finding. Not compoundable. | FDA December 2024 PCAC notice, and FDA's safety-risk page re-read on August 22, 2026. |
| CJC-1295 CJC-1295 related bulk drug substances | PCAC reviewNot compoundable | Not currently Category 1. FDA PCAC reviewed CJC-1295-related bulk substances in December 2024; no current Category 1 listing identified. The substance sits in FDA's 'nominated but withdrawn' table, where FDA continues to publish its safety-risk finding. Not compoundable. | FDA December 2024 PCAC notice, and FDA's safety-risk page re-read on August 22, 2026. |
| Thymosin alpha-1 Thymosin alpha-1 free base and acetate | PCAC reviewNot compoundable | Not currently Category 1. FDA PCAC reviewed thymosin alpha-1-related bulk substances in December 2024; no current Category 1 listing identified. The substance sits in FDA's 'nominated but withdrawn' table, where FDA continues to publish its safety-risk finding. Not compoundable. | FDA December 2024 PCAC notice, and FDA's safety-risk page re-read on August 22, 2026. |
| Selank Selank acetate / TP-7 | Not compoundable | Not currently Category 1. Selank acetate (TP-7) sits in FDA's 'nominated but withdrawn' table, where FDA continues to publish a safety-risk finding for it. It is not on the 503A Bulks List, was not on the July 2026 PCAC agenda, and is not compoundable. | FDA's safety-risk page, re-read line by line on August 22, 2026, and the current 503A category page. |
| Retatrutide Triple GIP/GLP-1/glucagon receptor agonist | InvestigationalNot compoundable | Investigational. FDA explicitly states retatrutide cannot be used in compounding under federal law. Enforcement pressure sharpened in mid-2026: FDA's Import Alert 66-80, republished August 13, 2026, includes import entries keyed to the word 'Retatrutide'; the UK MHRA said on July 24, 2026 that anyone selling retatrutide in the UK is doing so illegally; and on August 12, 2026 Eli Lilly filed six lawsuits against research-use-only sellers, a compounding pharmacy, and a med spa, arguing the 'research use only' label is pretext for selling an unapproved new drug. Those complaints are allegations — no defendant has been found liable. No ruling, injunction, or settlement in the Lilly cases as of August 22, 2026. | FDA GLP-1 compounding safety page, FDA Import Alert 66-80, and the August 12, 2026 Eli Lilly filings and public statement. |
| Cagrilintide Amylin analog | InvestigationalNot compoundable | Investigational. FDA explicitly states cagrilintide cannot be used in compounding under federal law. | FDA GLP-1 compounding safety page. |